Perrigo's revenue declined 3% (0.7% from pricing and 2.4% from volume/mix) and adjusted earnings per share fell 12% in the second quarter. 2026 guidance for a 3% sales decline and $2.15 in adjusted EPS, both at the midpoint, was reaffirmed. Shares rose 23% in Aug. 5 intraday trading.
Perrigo is now more tapped into the higher-margin branded consumer health market, which should act as a tailwind to the top and bottom lines.
By expanding its business to focus more on branded products, Perrigo now faces stiffer competition from larger consumer healthcare product manufacturers.
|
Metric
|
PRGO
|
PG
|
HLN
|
|---|---|---|---|
Price/Earnings (Normalized) | 5.83 | 21.45 | 19.27 |
Price/Book Value | 0.80 | 6.27 | 1.88 |
Price/Sales | 0.49 | 4.05 | 2.77 |
Price/Cash Flow | 8.34 | 18.37 | 14.28 |
|
Metric
|
PRGO
|
PG
|
HLN
|
|---|---|---|---|
Quick Ratio | 1.05 | 0.41 | 0.51 |
Current Ratio | 2.32 | 0.68 | 0.69 |
Interest Coverage | −8.88 | 23.74 | 7.45 |
|
Metric
|
PRGO
|
PG
|
HLN
|
|---|---|---|---|
Return on Assets (Normalized) | −2.11% | 13.14% | 5.49% |
Return on Equity (Normalized) | −5.54% | 31.34% | 10.94% |
Return on Invested Capital (Normalized) | −0.64% | 19.01% | 8.05% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|BZb@$X< | LOCK|!Jw< | $68B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|HZ$#mxR | LOCK|!lw$f | $42B | |||
| Haleon PLC ADR
HLN
| LOCK|D^&>#!y | LOCK|gQf | $40B | |||
| Zoetis Inc Class A
ZTS
| LOCK|#jzzFX# | LOCK|<y& | $30B | |||
| Viatris Inc
VTRS
| LOCK|@!X>W!! | LOCK|<g | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|$@M | LOCK|yL | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|h!p%f> | LOCK|D@g | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|%&fdqC> | LOCK|sKQ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|@TN#!< | LOCK|@c>Y | $2B |
United States